The identification of the furin–TGF-β/ERK axis as a tumor-promoting pathway provides opportunity for combinatorial treatments, targeting furin and TGF-β or ERK simultaneously, and improving therapeutic benefit whilst reducing off-target effects. The gene discussed is TGFB1; the disease is neoplasm.